Medical implications of erectile dysfunction

Medical Clinics of North America

Volumn 95, Issue 1, 2011, Pages 213-221

  Berookhim, Boback M ^a   Bar Chama, Natan ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Endothelial dysfunction; Erectile dysfunction; LUTS

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; TADALAFIL; TESTOSTERONE;

AGING; ALZHEIMER DISEASE; ANDROGEN DEFICIENCY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; EPILEPSY; ERECTILE DYSFUNCTION; HORMONE SUBSTITUTION; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; MALE SEXUAL DYSFUNCTION; NEUROLOGIC DISEASE; OBESITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT RESPONSE;

AGING; CARDIOVASCULAR DISEASES; ERECTILE DYSFUNCTION; HUMANS; MALE; PRIMARY HEALTH CARE; TESTOSTERONE; URINARY INCONTINENCE;

EID: 78649358348     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.08.020     Document Type: Review

References (55)

1. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54.
2. Laumann E.O., West S., Glasser D., et al. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med 2007, 4:57.
3. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000, 163:460.
4. Lue T.F. Erectile dysfunction. N Engl J Med 2000, 342:1802.
5. Giuliano F.A., Leriche A., Jaudinot E.O., et al. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004, 64:1196.
6. Sairam K., Kulinskaya E., Boustead G.B., et al. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 2001, 88:68.
7. Cho N.H., Ahn C.W., Park J.Y., et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med 2006, 23:198.
8. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005, 2:785.
9. Kapoor D., Aldred H., Clark S., et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007, 30:911.
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486.
11. Nikoobakht M., Nasseh H., Pourkasmaee M. The relationship between lipid profile and erectile dysfunction. Int J Impot Res 2005, 17:523.
12. Roumeguere T., Wespes E., Carpentier Y., et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003, 44:355.
13. Sullivan M.E., Miller M.A., Bell C.R., et al. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study. Int Angiol 2001, 20:195.
14. Bank A.J., Kelly A.S., Kaiser D.R., et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006, 11:251.
15. Solomon H., Samarasinghe Y.P., Feher M.D., et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006, 60:141.
16. Thompson I.M., Tangen C.M., Goodman P.J., et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294:2996.
17. Inman B.A., Sauver J.L., Jacobson D.J., et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009, 84:108.
18. Araujo A.B., Travison T.G., Ganz P., et al. Erectile dysfunction and mortality. J Sex Med 2009, 6:2445.
19. Bohm M., Baumhakel M., Teo K., et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010, 121:1439.
20. Montorsi P., Ravagnani P.M., Galli S., et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005, 96:19M.
21. Guay A.T. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin N Am 2007, 36:453.
22. Billups K.L., Bank A.J., Padma-Nathan H., et al. Erectile dysfunction is a marker for cardiovascular disease: results of the Minority Health Institute Expert Advisory Panel. J Sex Med 2005, 2:40.
23. Tamler R., Bar-Chama N. Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. Int J Impot Res 2008, 20:370.
24. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115.
25. Jackson G., Montorsi P., Adams M.A., et al. Cardiovascular aspects of sexual medicine. J Sex Med 2010, 7:1608.
26. Kaiser D.R., Billups K., Mason C., et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004, 43:179.
27. Chiurlia E., D'Amico R., Ratti C., et al. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005, 46:1503.
28. Kaya C., Uslu Z., Karaman I. Is endothelial function impaired in erectile dysfunction patients?. Int J Impot Res 2006, 18:55.
29. Bonetti P.O., Pumper G.M., Higano S.T., et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44:2137.
30. Rozanski A., Qureshi E., Bauman M., et al. Peripheral arterial responses to treadmill exercise among healthy subjects and atherosclerotic patients. Circulation 2001, 103:2084.
31. Kuvin J.T., Patel A.R., Sliney K.A., et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003, 146:168.
32. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338:1397.
33. Rosano G.M., Aversa A., Vitale C., et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005, 47:214.
34. Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999, 281:537.
35. Boyle P., Robertson C., Mazzetta C., et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU Int 2003, 92:719.
36. Braun M.H., Sommer F., Haupt G., et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical " aging male" symptoms? Results of the " Cologne Male Survey" . Eur Urol 2003, 44:588.
37. Blanker M.H., Bohnen A.M., Groeneveld F.P., et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001, 49:436.
38. Bloch W., Klotz T., Loch C., et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997, 33:1.
39. Roehrborn C., McVary K.T., Elbion-Mboussa A., et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008, 180:1228.
40. Reilly C.M., Stopper V.S., Mills T.M. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997, 18:26.
41. Uckert S., Sormes M., Kedia G., et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008, 71:526.
42. Somani B., Khan S., Donat R. Screening for metabolic syndrome and testosterone deficiency in patients with erectile dysfunction: results from the first UK prospective study. BJU Int 2010, 106:688.
43. Rhoden E.L., Teloken C., Mafessoni R., et al. Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction?. Int J Impot Res 2002, 14:167.
44. Corona G., Mannucci E., Mansani R., et al. Aging and pathogenesis of erectile dysfunction. Int J Impot Res 2004, 16:395.
45. Steidle C., Schwartz S., Jacoby K., et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003, 88:2673.
46. O'Carroll R., Shapiro C., Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf) 1985, 23:527.
47. Wang C., Swerdloff R.S., Iranmanesh A., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000, 85:2839.
48. Carani C., Granata A.R., Bancroft J., et al. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995, 20:743.
49. O'Connor D.B., Archer J., Wu F.C. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004, 89:2837.
50. Buvat J., Maggi M., Gooren L., et al. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010, 7:1627.
51. Corona G., Mannucci E., Petrone L., et al. NCEP-ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of hypogonadism in male patients with sexual dysfunction. J Sex Med 2007, 4:1038.
52. Corona G., Mannucci E., Petrone L., et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006, 18:190.
53. Shores M.M., Matsumoto A.M., Sloan K.L., et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006, 166:1660.
54. Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007, 116:2694.
55. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448.